DETAILS, FICTION AND CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY

In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, members will obtain ABBV-744 and ruxolitinib. Members will acquire treatment till sickness progression or perhaps the contributors are not able to tolerate the study drugs.- Participant eaten grapefruit or grapefruit solutions within three days prior to the first dos